Anatomy and Mammographic Technique

◊  >90% of nipples contain 5–9 ductal orifices

(b)  multiple other blind-ending orifices: connected to sebaceous glands of 1–4 cm in length

√  bilateral symmetric enhancement pattern of normal nipple:

√  1–2 mm superficial layer of intense linear enhancement

√  underlying region of nonenhancement deep to dermis


lactiferous ducts coalesce in subareolar region into 5–8 mm wide lactiferous sinuses exiting in the central portion of nipple; organized into

(a)  central ducts: extending to chest wall

(b)  peripheral ducts: arranged in a radial fashion

Main lactiferous duct → branches dichotomously into segmental duct → subsegmental duct → terminal duct → blunt-ending acinus

Terminal Duct Lobular Unit (TDLU)

(1)  Extralobular terminal duct

Histo:   lined by columnar cells + prominent coat of elastic fibers + outer layer of myoepithelium

(2)  Lobule

(a)  intralobular terminal duct

Histo:   lined by 2 layers of cuboidal cells + outer layer of myoepithelium (for milk propulsion)

Significance:   invasive ductal, papillary, mucinous, medullary adenoid cystic cancers arise from ductal epithelium in TDLU and most commonly appear as spiculated irregular masses ± calcifications / developing asymmetries

(b)  ductules / acini

(c)  intralobular connective tissue

Size:     1–2 (range, 1–8) mm in diameter


(a)  reproductive age: cyclic proliferation (up to time of ovulation) + cyclic involution (during menstruation)

(b)  post menopause: regression with fatty replacement


TDLU is the site of fibroadenoma, epithelial cyst, apocrine metaplasia, adenosis (= proliferation of ductules + lobules), epitheliosis (= proliferation of mammary epithelial cells within preexisting ducts + lobules), ductal + lobular carcinoma in situ, infiltrating ductal + lobular carcinoma

Components of Normal Breast Parenchyma

1.   Nodular densities surrounded by fat

(a)  1–2 mm = normal lobules

(b)  3–9 mm = adenosis

2.   Linear densities

=  ducts and their branches + surrounding elastic tissue

3.   Structureless ground-glass density

=  stroma / fibrosis with concave contours

Parenchymal Breast Pattern (László Tabár)

Effect of breast density on sensitivity:

women in their 40s have a 68% higher risk of a FN screening mammogram compared to older women

Recommendation:   perform mammography during 1st week of menstrual cycle

Inter- and intraobserver variability on breast density:

›  low reliability of interreader density agreement (κ = 0.59)

›  imperfect intrareader agreement (κ = 0.72)

Factors affecting breast density between mammograms:

body mass index, weight changes, age, HRT, dietary intake


Overall odds ratio of breast cancer for > 75% tissue density:

›  compared to 10% density 4.74

›  with interval cancer developed in 1 year 17.81

Relative risk of cancer associated with breast density:

›  breast tissue density of 50–74% 2.92

›  breast tissue density of > 75% 4.64

Pattern I

named QDY = quasi dysplasia (for Wolfe classification)

√  concave contour from Cooper’s ligaments

√  evenly scattered 1–2 mm nodular densities (= normal terminal ductal lobular units)

√  oval-shaped / circular lucent areas (= fatty replacement)

Pattern II

similar to N1 (Wolfe)

√  total fatty replacement

√  NO nodular densities

Pattern III

similar to P1 (Wolfe)

√  normal parenchyma occupying < 25% of breast volume in retroareolar location

Pattern IV = adenosis pattern

similar to P2 (Wolfe)

Cause:    hypertrophy + hyperplasia of acini within lobules

Histo:  small ovoid proliferating cells with rare mitoses

√  scattered 3–7 mm nodular densities (= enlarged terminal ductal lobular units) = adenosis

√  thick linear densities (= periductal elastic tissue proliferation with fibrosis) = fibroadenosis

√  no change with increasing age (genetically determined)

Pattern V

similar to DY (Wolfe)

√  uniformly dense parenchyma with smooth contour (= extensive fibrosis)

Enhancement of Normal Parenchyma on MR

=  Background Parenchymal Enhancement (BPE)

◊  Breast enhancement does NOT correlate with breast density

•  varies among women + within same woman over time

Proper enhancement present if:

›  veins contrasted on MIP

›  both internal mammary arteries depicted

›  nipple enhances

Common pattern of enhancement:

√  bilateral symmetric diffuse enhancement:

√  slow minimal / early enhancement

√  persistent delayed enhancement

√  linear patchy enhancement

√  confluent enhancement on late dynamic scan

Distribution of enhancement:

√  bilateral symmetric enhancement with

(a)  moderate / marked degree of BPE

(b)  diffuse / regional distribution

(c)  homogeneous / internally stippled

√  “picture framing” of vascular inflow = enhancement commonly begins in periphery + gradually becomes apparent in more central breast tissue

√  scattered innumerable 9–10 mm foci of enhancement

√  geographic areas of symmetric regional enhancement

√  multiple larger symmetric areas of enhancement (DDx: asymmetry suggest malignancy)

BPE Effect on Interpretation of MR Images:

1.   Falsely positive ← focal / regional / asymmetric background parenchymal enhancement

2.   Falsely negative ← moderate / marked BPE

Classification of Background Parenchymal Enhancement:

Minimal    < 25% of glandular tissue
Mild 25–50%
Moderate 50–75%
Marked    > 75%

Hormonal Influence on BPE

1.   Menstruation

√  enhancement high during days 21–28 and days 1–6 after menstruation + low during days 7–20

2.   Lactation

◊  Breast involution after lactation takes 3 months

Note:  NO impairment in cancer detection in lactating patients!

Breast-feeding:   safe after contrast-enhanced MRI ← minute amounts of Gd in breast milk

3.   Postmenopausal period without HRT

√  decrease in fibroglandular tissue → degree of BPE typically less than that in premenopausal women

4.   Hormone replacement therapy (HRT)

√  increase in BPE in amount + degree + distribution with great interindividual variations:

◊  Hormonal effect reverses after 30–60 days

5.   Endocrine antihormonal therapy

Antiestrogenic agents:   selective estrogen receptor modulators, aromatase inhibitors

√  significant decrease in amount of fibroglandular tissue + cysts + BPE

√  effect on BPE evident early in treatment (< 90 days)

√  tamoxifen rebound after medication discontinued:

√  global / focal increase in BPE

6.   Oophorectomy → decrease in BPE

MRI preferably performed during 2nd week of menstrual cycle!

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jun 29, 2017 | Posted by in GENERAL RADIOLOGY | Comments Off on Anatomy and Mammographic Technique

Full access? Get Clinical Tree

Get Clinical Tree app for offline access